Table S4: Grade 1 or Higher Solicited Symptoms after Any Vaccination by Maximum Reported Severity

|  | Placebo (N=12)  n (%) | | | | 20 µg (N=18)  n (%) | | | | 100 µg (N=18)  n (%) | | | | Overall (N=48)  n (%) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Any | Gr 1 | Gr 2 | Gr 3 | Any | Gr 1 | Gr 2 | Gr 3 | Any | Gr 1 | Gr 2 | Gr 3 | Any |
| Any Solicited Symptom | 11 (91.7) | 6 (50.0) | 2 (16.7) | 3 (25.0) | 18 (100.0) | 3 (16.7) | 10 (55.6) | 5 (27.8) | 17 (94.4) | 2 (11.1) | 10 (55.6) | 5 (27.8) | 46 (95.8) |
| Local Symptom | 7 (58.3) | 6 (50.0) | 1 (8.3) | 0 (0.0) | 18 (100.0) | 5 (27.8) | 11 (61.1) | 2 (11.1) | 17 (94.4) | 6 (33.3) | 10 (55.6) | 1 (5.6) | 42 (87.5) |
| Pain | 6 (50.0) | 5 (41.7) | 1 (8.3) | 0 (0.0) | 18 (100.0) | 9 (50.0) | 8 (44.4) | 1 (5.6) | 15 (83.3) | 9 (50.0) | 5 (27.8) | 1 (5.6) | 39 (81.3) |
| Tenderness | 4 (33.3) | 4 (33.3) | 0 (0.0) | 0 (0.0) | 18 (100.0) | 8 (44.4) | 10 (55.6) | 0 (0.0) | 16 (88.9) | 7 (38.9) | 8 (44.4) | 1 (5.6) | 38 (79.2) |
| Erythema/Skin  Discoloration | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (22.2) | 2 (11.1) | 1 (5.6) | 1 (5.6) | 3 (16.7) | 2 (11.1) | 1 (5.6) | 0 (0.0) | 7 (14.6) |
| Swelling/Hardening  or Thickening | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (16.7) | 2 (11.1) | 1 (5.6) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 4 (8.3) |
| Systemic Symptom | 10 (83.3) | 5 (41.7) | 2 (16.7) | 3 (25.0) | 18 (100.0) | 9 (50.0) | 5 (27.8) | 4 (22.2) | 16 (88.9) | 2 (11.1) | 9 (50.0) | 5 (27.8) | 44 (91.7) |
| Headache | 5 (41.7) | 2 (16.7) | 1 (8.3) | 2 (16.7) | 15 (83.3) | 12 (66.7) | 3 (16.7) | 0 (0.0) | 15 (83.3) | 8 (44.4) | 7 (38.9) | 0 (0.0) | 35 (72.9) |
| Malaise | 3 (25.0) | 2 (16.7) | 0 (0.0) | 1 (8.3) | 17 (94.4) | 11 (61.1) | 5 (27.8) | 1 (5.6) | 15 (83.3) | 3 (16.7) | 10 (55.6) | 2 (11.1) | 35 (72.9) |
| Chills/Shivering | 3 (25.0) | 2 (16.7) | 0 (0.0) | 1 (8.3) | 13 (72.2) | 7 (38.9) | 3 (16.7) | 3 (16.7) | 13 (72.2) | 7 (38.9) | 4 (22.2) | 2 (11.1) | 29 (60.4) |
| Generalized  Myalgia/Muscle Pain | 4 (33.3) | 4 (33.3) | 0 (0.0) | 0 (0.0) | 9 (50.0) | 4 (22.2) | 5 (27.8) | 0 (0.0) | 11 (61.1) | 6 (33.3) | 3 (16.7) | 2 (11.1) | 24 (50.0) |
| Nausea | 4 (33.3) | 2 (16.7) | 2 (16.7) | 0 (0.0) | 7 (38.9) | 6 (33.3) | 1 (5.6) | 0 (0.0) | 12 (66.7) | 8 (44.4) | 2 (11.1) | 2 (11.1) | 23 (47.9) |
| Arthralgia/Joint Pain | 1 (8.3) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 6 (33.3) | 5 (27.8) | 1 (5.6) | 0 (0.0) | 8 (44.4) | 4 (22.2) | 3 (16.7) | 1 (5.6) | 15 (31.3) |
| Abdominal Pain | 2 (16.7) | 1 (8.3) | 0 (0.0) | 1 (8.3) | 3 (16.7) | 2 (11.1) | 1 (5.6) | 0 (0.0) | 5 (27.8) | 4 (22.2) | 1 (5.6) | 0 (0.0) | 10 (20.8) |
| Fever | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (22.2) | 3 (16.7) | 1 (5.6) | 0 (0.0) | 4 (22.2) | 3 (16.7) | 1 (5.6) | 0 (0.0) | 8 (16.7) |
| Diarrhea | 1 (8.3) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 4 (22.2) | 4 (22.2) | 0 (0.0) | 0 (0.0) | 2 (11.1) | 2 (11.1) | 0 (0.0) | 0 (0.0) | 7 (14.6) |
| Vomiting | 2 (16.7) | 1 (8.3) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 3 (6.3) |

*N = Total number of volunteers in the safety analysis population per group  
n = For the 'Any' columns, cells present the number of volunteers with at least one Grade 1 or higher event (volunteers with >1 reported event are counted only once). For the by-grade columns, cells present the number of volunteers with at least one event at the maximum reported severity (volunteers with >1 reported event are counted only once and only at the maximum reported severity).  
% = Percentage of volunteers in each category, i.e., 100 x n/N  
Gr = Grade  
Solicited symptoms are reported through 7 days post-vaccination (i.e., 8-day follow-up period) and are considered related to IP.  
Maximum reported severity over all events was grade 3.  
Specific events are presented by descending overall frequency of volunteers with an event.*